Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited has announced promising results from their study CUV151, showing that their drug afamelanotide significantly aids in DNA repair after UV damage, reducing the expression of genes associated with skin damage by more than threefold. The findings, presented at the British Association of Dermatologists meeting, could offer new protective treatments for individuals prone to sunburn and skin cancer, particularly those with fair skin types.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.